CRD-B 📈 Crawford & - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2246331076
CRD-B: Claims Management, Insurance Services, Risk Management, Outsourcing Solutions
Crawford & Company provides claims management and outsourcing solutions for carriers, brokers, and corporations in the United States, the United Kingdom, Europe, Canada, Australia, Asia, and Latin America. The North America Loss Adjusting segment provides claims management services to insurance carriers and self-insured entities risk, including property, public liability, automobile liability, and marine insurances. The International Operations segment provides claims management and adjusting services to insurance carriers and self-insured entities; and field investigation and the evaluation and resolution of property and casualty insurance claims. The Broadspire segment offers claims management services, including workers' compensation, liability, property, accident and health, and disability claims management; accident and health claims programs; disability and leave management services, as well as legal services, risk management information, and consultative analytical services. This segment also provides medical management services; administration services; physician review services, as well as claims and risk management services and technology solutions; desktop claim adjusting and evaluation of claims; initial loss reporting services for claimants; and loss mitigation services, such as medical bill review, medical case management and vocational rehabilitation services. The Platform Solutions segment offers managed repair service and outsourced contractor management to national and regional personal and commercial insurance carriers; services to insurance companies on losses caused by all types of natural disasters, such as fires, hailstorms, hurricanes, earthquakes, floods, as well as man-made disasters, such as oil spills, chemical releases, and explosions; and outsourced subrogation claims management, recovery, and consultative services for the property and casualty insurance industry. The company was founded in 1941 and is headquartered in Atlanta, Georgia. Web URL: https://www.crawco.com
Additional Sources for CRD-B Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CRD-B Stock Overview
Market Cap in USD | 559m |
Sector | Financial Services |
Industry | Insurance Brokers |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 1990-01-12 |
CRD-B Stock Ratings
Growth 5y | 26.2% |
Fundamental | 25.0% |
Dividend | 57.1% |
Rel. Strength Industry | -98.2 |
Analysts | 5/5 |
Fair Price Momentum | 10.61 USD |
Fair Price DCF | 11.43 USD |
CRD-B Dividends
Dividend Yield 12m | 2.54% |
Yield on Cost 5y | 3.27% |
Annual Growth 5y | 5.39% |
Payout Consistency | 81.4% |
CRD-B Growth Ratios
Growth Correlation 3m | -29.5% |
Growth Correlation 12m | -0.5% |
Growth Correlation 5y | 54.3% |
CAGR 5y | 5.15% |
CAGR/Mean DD 5y | 0.22 |
Sharpe Ratio 12m | 0.06 |
Alpha | -25.19 |
Beta | 0.75 |
Volatility | 36.59% |
Current Volume | 47.8k |
Average Volume 20d | 11.8k |
What is the price of CRD-B stocks?
As of December 21, 2024, the stock is trading at USD 11.01 with a total of 47,800 shares traded.
Over the past week, the price has changed by -0.09%, over one month by +2.23%, over three months by -3.08% and over the past year by +0.60%.
As of December 21, 2024, the stock is trading at USD 11.01 with a total of 47,800 shares traded.
Over the past week, the price has changed by -0.09%, over one month by +2.23%, over three months by -3.08% and over the past year by +0.60%.
Is Crawford & a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Crawford & is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.02 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRD-B as of December 2024 is 10.61. This means that CRD-B is currently overvalued and has a potential downside of -3.63%.
Neither. Based on ValueRay Fundamental Analyses, Crawford & is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.02 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRD-B as of December 2024 is 10.61. This means that CRD-B is currently overvalued and has a potential downside of -3.63%.
Is CRD-B a buy, sell or hold?
Crawford & has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy CRD-B.
Crawford & has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy CRD-B.
- Strong Buy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for CRD-B stock price target?
According to ValueRays Forecast Model, CRD-B Crawford & will be worth about 11.5 in December 2025. The stock is currently trading at 11.01. This means that the stock has a potential upside of +4.36%.
According to ValueRays Forecast Model, CRD-B Crawford & will be worth about 11.5 in December 2025. The stock is currently trading at 11.01. This means that the stock has a potential upside of +4.36%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 13 | 18.1% |
Analysts Target Price | 12.5 | 13.5% |
ValueRay Target Price | 11.5 | 4.4% |